RxDoctor Payments Data

Krista Hobbs, PA

Physician Assistant · Fredericksburg, VANPI 1235656208

Payments from drug & device makers

$3,006in general payments, 2019–2025

Across 106 payments — averaging $28.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novocure Inc.$471
  • Johnson & Johnson$313
  • Incyte Corporation$151
  • Merck$144
  • Amgen$122
  • Seagen Inc.$114
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$2,61687%
  • Education$39013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,006 in reported general payments places this provider in the 85th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$44,664
Medicare patients
188
Services billed
443

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib20$320,961
JakafiRuxolitinib Phosphate13$224,256
EliquisApixaban21$13,236
Ondansetron OdtOndansetron28$1,662
Lidocaine-PrilocaineLidocaine/Prilocaine57$679
Potassium Chloride31$663
Anastrozole42$661
Hydroxyurea19$510
Dexamethasone25$493
Prochlorperazine Maleate20$408
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen15$318
Acyclovir20$306
LoperamideLoperamide Hcl13$212
Mirtazapine11$167
Tramadol Hcl18$111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$92$320,96120 claims
Incyte CorporationJakafi$151$224,25613 claims
PfizerEliquis$110$13,23621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →